全文获取类型
收费全文 | 131篇 |
免费 | 5篇 |
出版年
2017年 | 1篇 |
2015年 | 1篇 |
2014年 | 4篇 |
2013年 | 3篇 |
2012年 | 3篇 |
2011年 | 2篇 |
2010年 | 3篇 |
2008年 | 1篇 |
2007年 | 2篇 |
2006年 | 3篇 |
2003年 | 1篇 |
2002年 | 1篇 |
1998年 | 1篇 |
1997年 | 2篇 |
1996年 | 4篇 |
1995年 | 3篇 |
1994年 | 1篇 |
1993年 | 2篇 |
1992年 | 2篇 |
1990年 | 1篇 |
1989年 | 3篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1985年 | 2篇 |
1982年 | 1篇 |
1981年 | 3篇 |
1980年 | 1篇 |
1975年 | 3篇 |
1974年 | 1篇 |
1972年 | 1篇 |
1959年 | 2篇 |
1958年 | 6篇 |
1957年 | 3篇 |
1956年 | 9篇 |
1955年 | 8篇 |
1954年 | 12篇 |
1953年 | 6篇 |
1952年 | 11篇 |
1951年 | 6篇 |
1950年 | 2篇 |
1949年 | 3篇 |
1948年 | 8篇 |
1947年 | 1篇 |
排序方式: 共有136条查询结果,搜索用时 578 毫秒
1.
2.
3.
Presence and significance of desoxyribose nucleoprotein in the purulent pleural exudates of patients 总被引:1,自引:0,他引:1
4.
BACKGROUND: Morbidity management is a core component of the global programme for the elimination of lymphatic filariasis. In a double-blind clinical trial, the tolerability and efficacy of Daflon (500 mg) + DEC (25 mg) or DEC (25 mg) alone, twice daily for 90 days, was studied in 26 patients with bancroftian filarial lymphoedema. RESULTS: None of the patients in either drug group reported any adverse reaction throughout the treatment period (90 days). Haematological and biochemical parameters were within normal limits and there was no significant difference between the pre-treatment (day 0) and post-treatment (day 90) values. The group receiving Daflon showed significant reduction in oedema volume from day 90 (140.6 PlusMinus; 18.8 ml) to day 360 (71.8 PlusMinus; 20.7 ml) compared to the pre-treatment (day 0, 198.4 PlusMinus; 16.5 ml) value. This accounted for a 63.8% reduction in oedema volume by day 360 (considering the pre-treatment (day 0) as 100%). In the DEC group, the changes in oedema volume (between day 1 and day 360) were not significant when compared to the pre-treatment (day 0) value. The percentage reduction at day 360 was only 9%, which was not significant (P > 0.05). CONCLUSION: This study has shown that Daflon (500 mg, twice a day for 90 days) is both safe and efficacious in reducing oedema volume in bancroftian filarial lymphoedema. Further clinical trials are essential for strengthening the evidence base on the role of this drug in the morbidity management of lymphatic filariasis. 相似文献
5.
6.
Paula H Suss Luiz Guilherme A Capriglione Fabiane Barchiki Lye Miyague Danielle Jackowski Letícia Fracaro Andressa V Schittini Alexandra C Senegaglia Carmen LK Rebelatto Márcia Olandoski Alejandro Correa Paulo RS Brofman 《Experimental biology and medicine (Maywood, N.J.)》2015,240(7):969-978
The development of new therapeutic strategies is necessary to reduce the worldwide social and economic impact of cardiovascular disease, which produces high rates of morbidity and mortality. A therapeutic option that has emerged in the last decade is cell therapy. The aim of this study was to compare the effect of transplanting human umbilical cord-derived stromal cells (UCSCs), human umbilical cord blood-derived endothelial cells (UCBECs) or a combination of these two cell types for the treatment of ischemic cardiomyopathy (IC) in a Wistar rat model. IC was induced by left coronary artery ligation, and baseline echocardiography was performed seven days later. Animals with a left ventricular ejection fraction (LVEF) of ≤40% were selected for the study. On the ninth day after IC was induced, the animals were randomized into the following experimental groups: UCSCs, UCBECs, UCSCs plus UCBECs, or vehicle (control). Thirty days after treatment, an echocardiographic analysis was performed, followed by euthanasia. The animals in all of the cell therapy groups, regardless of the cell type transplanted, had less collagen deposition in their heart tissue and demonstrated a significant improvement in myocardial function after IC. Furthermore, there was a trend of increasing numbers of blood vessels in the infarcted area. The median value of LVEF increased by 7.19% to 11.77%, whereas the control group decreased by 0.24%. These results suggest that UCSCs and UCBECs are promising cells for cellular cardiomyoplasty and can be an effective therapy for improving cardiac function following IC. 相似文献
7.
8.
9.
10.